Taksta (fusidic acid) / Aceragen  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Taksta (fusidic acid) / Aceragen
NCT00948142: Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

Completed
2
198
US
CEM-102, fusidic acid, Linezolid, Zyvox
Arrevus Inc.
Skin Diseases, Bacterial
03/10
03/10
NCT01756924: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Checkmark A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination with Oral Rifampin Compared with Standard of Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction.
Terminated
2
14
US
CEM-102, fusidic acid, IV or Oral standard of care antibiotics, vancomycin, daptomycin, linezolid, rifampin, ceftriaxone, cefazolin, ceftaroline, nafcillin, oxacillin, ciprofloxacin, levofloxacin, co-trimoxazole, Rifampin
Arrevus Inc.
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
07/14
07/14
NCT05105035: Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients

Not yet recruiting
2
100
NA
Ceftazidime or meropenem, ARV-1801, Placebo
Arrevus Inc.
Melioidosis
01/23
01/23

Download Options